Skin Irritation Clinical Trial
Official title:
The Effect of Oral Vitamin D (Cholecalciferol) Supplementation After Topical Application With Valchlor
Verified date | December 2021 |
Source | University Hospitals Cleveland Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this research study is to evaluate the effects of an oral Vitamin D on the body's immune system. An interest has been growing because studies have shown that Vitamin D may reduce inflammation and harmful effects in the body, however, the best dose for Vitamin D is still unknown. Inflammation is the body's physical response to infection, injury, or long term disease. Pain, redness, heat, and sometimes loss of function are all signs of inflammation in the body. This study will look at product use, testing skin irritation in healthy volunteers and seeing how Vitamin D may help stop or reduce inflammation and skin irritation, which could one day help doctors prescribe Vitamin D to patients with long term disease to relieve their symptoms.
Status | Completed |
Enrollment | 33 |
Est. completion date | October 1, 2018 |
Est. primary completion date | October 1, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Must be in general good health - Fitzpatrick Skin Type I-VI - Able to list all current medications and medical conditions - Capable of giving informed consent Exclusion Criteria: - Women who are pregnant, nursing, or who may become pregnant in the next 3 months - Participants taking illegal drugs - Currently taking ketoconazole, colestipol, cholestyramine, phenobarbitol, phenytoin, or mineral oil - Currently consuming 800IU or more of vitamin D a day - Subjects whose BMI are > 40 |
Country | Name | City | State |
---|---|---|---|
United States | University Hospitals | Cleveland | Ohio |
Lead Sponsor | Collaborator |
---|---|
University Hospitals Cleveland Medical Center | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in skin erythema | Skin erythema (redness) will be quantified using a CR300 chromameter. The difference in erythema between exposed and non-exposed skin will be calculated after valchlor exposure | Up to 1 week after mechloroethamine exposure | |
Secondary | Change in skin thickness | Skin thickness, an acute measure of edema, was quantified using a Mitutoyo 9mm dial caliper. Thickness measurements will be repeated in triplicate and the mean was used for all calculations. The difference in thickness between exposed and non-exposed skin will be calculated after valchlor exposure. | Up to 1 week after mechloroethamine exposure | |
Secondary | Change in TNF-alpha expression | A 6 mm punch biopsy specimen will be obtained from the valchlor exposure site 48hr after exposure. RNA will be extracted from fresh frozen punch biopsies using the RNeasy Lipid Mini Kit, and tissue mRNA expression of TNF-a will be quantified | Up to 120 hours after mechloroethamine exposure | |
Secondary | Change in iNOS expression | A 6 mm punch biopsy specimen will be obtained from the valchlor exposure site 48hr after exposure. RNA will be extracted from fresh frozen punch biopsies using the RNeasy Lipid Mini Kit, and tissue mRNA expression of iNOS will be quantified | Up to 120 hours after mechloroethamine exposure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01806831 -
Efficacy and Safety of Biocellulose Sheet Containing Anti-hyperpigmentation Agent ("Biocellulose Mask", "Farhorm®") in Patients Receiving Laser Treatment
|
N/A | |
Completed |
NCT02297841 -
Repeated Insult Patch Test of Personal Lubricants
|
N/A | |
Completed |
NCT03397862 -
A Skin Irritation Assessment of Once-Weekly Corplex™ Donepezil Transdermal Delivery System
|
Phase 1 | |
Unknown status |
NCT01821274 -
A 21-Day Topical Safety Study of Diltiazem Hydrochloride Using a Cumulative Irritant Patch Test Design
|
Phase 1 | |
Completed |
NCT01892657 -
Cetaphil® Daily Facial Moisturizer With Sunscreen SPF 50+ - Human Repeat Insult Patch Test
|
Phase 4 | |
Withdrawn |
NCT02400320 -
Local Skin Safety Study of a Topical Pain Relief Spray Containing a Combination of Diclofenac, Methyl Salicylate, and Menthol
|
Phase 4 | |
Not yet recruiting |
NCT02645110 -
Evaluation of Effectiveness and Mildness of Whole-natural Hand-wash Formulations
|
N/A | |
Completed |
NCT01892410 -
Patch Test Skin Irritation/Sensitization of Cetaphil Restoraderm Skin Restoring Body Wash
|
N/A | |
Completed |
NCT01887860 -
Patch Test Skin Irritation/Sensitization of Cetaphil Daily Facial Moisturizer SPF 50
|
N/A | |
Completed |
NCT01887808 -
Repeat Insult Patch Test of Skin Irritation/Sensitization for Cetaphil Dermacontrol Oil Control Moisturizer SPF 30
|
N/A | |
Completed |
NCT01888887 -
Repeat Insult Patch Test of Skin Irritation/Sensitization for Cetaphil Daily Facial Cleanser
|
N/A | |
Completed |
NCT01892423 -
Repeat Insult Patch Test for Daily Advance Cetaphil Moisturizing Lotion
|
N/A |